With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Revolutionary ovarian cancer rapid test available Q4 2022
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The company also raised Rs 270 crore investment from Temasek in 2019
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Subscribe To Our Newsletter & Stay Updated
